Pfizer Inc.'s COVID-19 vaccine BNT162b2, developed in partnership with BioNTech SE, has reshaped the company's financial outlook and management expects the vaccine business will continue to be a contributor for the foreseeable future. One of the outstanding questions about the long-term viability of the business is if regulator booster shots will be needed, and Pfizer, at least, believes that may be the case.
The firm raised its financial guidance for the vaccine this year to $33bn versus a prior guidance of $26bn, a staggering sum that is unprecedented for any new drug or vaccine in the industry and